Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 6/20 | 0.39 |
| ▸ | PYGM | P11217 | 4/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.37 |
| ▸ | CCKBR | P32239 | 4/20 | 0.35 |
| ▸ | CCKAR | P32238 | 3/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897701 | 0.92 | SCN9A (0.39) | PYGLPYGMSCN9ACCKBRDPP4 | |
| SCHEMBL4893208 | 0.89 | CCKBR (0.36) | SCN9ACCKBRCCKARDPP4 | |
| SCHEMBL4894329 | 0.88 | SCN9A (0.35) | SCN9ACCKBRCCKARDPP4RIPK1 | |
| SCHEMBL4887286 | 0.88 | RIPK1 (0.37) | SCN9ACCKBRCCKARDPP4RIPK1 | |
| SCHEMBL4897302 | 0.88 | RIPK1 (0.34) | SCN9ADPP4RIPK1 | |
| SCHEMBL4891179 | 0.81 | DPP4 (0.47) | PYGLPYGMDPP4 | |
| SCHEMBL8274738 | 0.79 | SCN9A (0.49) | PYGLPYGMSCN9ACCKBRCCKAR | |
| SCHEMBL4897558 | 0.79 | SCN9A (0.35) | SCN9ACCKBRDPP4 | |
| SCHEMBL4889506 | 0.75 | RIPK1 (0.33) | SCN9ARIPK1 | |
| SCHEMBL4895620 | 0.74 | SCN9A (0.44) | SCN9ACCKBRCCKARRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | PYGL 1009/4885PYGM 1772/4885SCN9A 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.